<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39407875</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Monoclonal Antibodies for the Treatment of Ocular Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5815</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13195815</ELocationID><Abstract><AbstractText>Monoclonal antibodies (mAbs) have revolutionized the landscape of cancer therapy, offering unprecedented specificity and diverse mechanisms to combat malignant cells. These biologic agents have emerged as a cornerstone in targeted cancer treatment, binding to specific antigens on cancer cells and exerting their therapeutic effects through various mechanisms, including inhibition of signaling pathways, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). The unique ability of mAbs to engage the immune system and directly interfere with cancer cell function has significantly enhanced the therapeutic armamentarium against a broad spectrum of malignancies. mAbs were initially studied in oncology; however, today, treatments have been developed for eye diseases. This review discusses the current applications of mAbs for the treatment of ocular diseases, discussing the specificity and the variety of mechanisms by which these molecules exhibit their therapeutic effects. The benefits, drawbacks, effectiveness, and risks associated with using mAbs in ophthalmology are highlighted, focusing on the most relevant ocular diseases and mAbs currently in use. Technological advances have led to in vitro production methods and recombinant engineering techniques, allowing the development of chimeric, humanized, and fully human mAbs. Nowadays, many humanized mAbs have several applications, e.g., for the treatment of age-related macular disease, diabetic retinopathy, and uveitis, while studies about new applications of mAbs, such as for SARS-CoV-2 infection, are also currently ongoing to seek more efficient and safe approaches to treat this new ocular disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henriques</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Sciences School, Guarda Polytechnic Institute, Rua da Cadeia, 6300-035 Guarda, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Ana</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4240-8106</Identifier><AffiliationInfo><Affiliation>Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krambeck</LastName><ForeName>Karolline</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9645-4020</Identifier><AffiliationInfo><Affiliation>Health Sciences School, Guarda Polytechnic Institute, Rua da Cadeia, 6300-035 Guarda, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miguel</LastName><ForeName>Sónia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7274-0399</Identifier><AffiliationInfo><Affiliation>Health Sciences School, Guarda Polytechnic Institute, Rua da Cadeia, 6300-035 Guarda, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santini</LastName><ForeName>Antonello</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5505-3327</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Napoli Federico II, Via D. Montesano, 49-80131 Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zielińska</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology, Institute of Natural Fibres and Medicinal Plants-National Research Institute, Wojska Polskiego 71b, 60-630 Poznań, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souto</LastName><ForeName>Eliana B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0002-9737-6017</Identifier><AffiliationInfo><Affiliation>Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCD School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin 4, D04 V1W8 Dublin, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">diabetic retinopathy</Keyword><Keyword MajorTopicYN="N">monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">ocular diseases</Keyword><Keyword MajorTopicYN="N">uveitis</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39407875</ArticleId><ArticleId IdType="pmc">PMC11482488</ArticleId><ArticleId IdType="doi">10.3390/jcm13195815</ArticleId><ArticleId IdType="pii">jcm13195815</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Breedveld F. Therapeutic monoclonal antibodies. Lancet. 2000;355:735–740. doi: 10.1016/S0140-6736(00)01034-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)01034-5</ArticleId><ArticleId IdType="pubmed">10703815</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer V. An overview of monoclonal antibodies. Semin. Oncol. Nurs. 2019;35:150927. doi: 10.1016/j.soncn.2019.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.soncn.2019.08.006</ArticleId><ArticleId IdType="pubmed">31488319</ArticleId></ArticleIdList></Reference><Reference><Citation>Ecker D.M., Jones S.D., Levine H.L. The therapeutic monoclonal antibody market. mAbs. 2015;7:9–14. doi: 10.4161/19420862.2015.989042.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/19420862.2015.989042</ArticleId><ArticleId IdType="pmc">PMC4622599</ArticleId><ArticleId IdType="pubmed">25529996</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodríguez-Nava C., Ortuño-Pineda C., Illades-Aguiar B., Flores-Alfaro E., Leyva-Vázquez M.A., Parra-Rojas I., del Moral-Hernández O., Vences-Velázquez A., Cortés-Sarabia K., Alarcón-Romero L.d.C. Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of cancer. Biomedicines. 2023;11:1610. doi: 10.3390/biomedicines11061610.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11061610</ArticleId><ArticleId IdType="pmc">PMC10295864</ArticleId><ArticleId IdType="pubmed">37371712</ArticleId></ArticleIdList></Reference><Reference><Citation>McMaster P.D., Hudack S.S. The formation of agglutinins with lymph nodes. J. Exp. Med. 1935;61:783–805. doi: 10.1084/jem.61.6.783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.61.6.783</ArticleId><ArticleId IdType="pmc">PMC2133253</ArticleId><ArticleId IdType="pubmed">19870391</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Tank N.K., Dwiwedi P., Charan J., Kaur R., Sidhu P., Chugh V.K. Monoclonal antibodies: A review. Curr. Clin. Pharmacol. 2018;13:85–99. doi: 10.2174/1574884712666170809124728.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1574884712666170809124728</ArticleId><ArticleId IdType="pubmed">28799485</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues E.B., Farah M.E., Maia M., Penha F.M., Regatieri C., Melo G.B., Pinheiro M.M., Zanetti C.R. Therapeutic monoclonal antibodies in ophthalmology. Prog. Retin. Eye Res. 2009;28:117–144. doi: 10.1016/j.preteyeres.2008.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2008.11.005</ArticleId><ArticleId IdType="pubmed">19114125</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2011;2:1097–1105. doi: 10.1177/1947601911423031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1947601911423031</ArticleId><ArticleId IdType="pmc">PMC3411125</ArticleId><ArticleId IdType="pubmed">22866201</ArticleId></ArticleIdList></Reference><Reference><Citation>Penn J.S., Madan A., Caldwell R.B., Bartoli M., Caldwell R.W., Hartnett M.E. Vascular endothelial growth factor in eye disease. Prog. Retin. Eye Res. 2008;27:331–371. doi: 10.1016/j.preteyeres.2008.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2008.05.001</ArticleId><ArticleId IdType="pmc">PMC3682685</ArticleId><ArticleId IdType="pubmed">18653375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lad E.M., Finger R.P., Guymer R. Biomarkers for the Progression of Intermediate Age-Related Macular Degeneration. Ophthalmol. Ther. 2023;12:2917–2941. doi: 10.1007/s40123-023-00807-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40123-023-00807-9</ArticleId><ArticleId IdType="pmc">PMC10640447</ArticleId><ArticleId IdType="pubmed">37773477</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas C.J., Mirza R.G., Gill M.K. Age-Related Macular Degeneration. Med. Clin. N. Am. 2021;105:473–491. doi: 10.1016/j.mcna.2021.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcna.2021.01.003</ArticleId><ArticleId IdType="pubmed">33926642</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl A. The Diagnosis and Treatment of Age-Related Macular Degeneration. Dtsch. Arztebl. Int. 2020;117:513–520. doi: 10.3238/arztebl.2020.0513.</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2020.0513</ArticleId><ArticleId IdType="pmc">PMC7588619</ArticleId><ArticleId IdType="pubmed">33087239</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone E.M. Macular degeneration. Annu. Rev. Med. 2007;58:477–490. doi: 10.1146/annurev.med.58.111405.133335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.med.58.111405.133335</ArticleId><ArticleId IdType="pubmed">16922634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikushima W., Sakurada Y., Fukuda Y., Matsubara M., Kotoda Y., Sugiyama A., Kashiwagi K. A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result. Pharmaceuticals. 2023;16:562. doi: 10.3390/ph16040562.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16040562</ArticleId><ArticleId IdType="pmc">PMC10141467</ArticleId><ArticleId IdType="pubmed">37111318</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman H.R., Chan C.-C., Ferris F.L., Chew E.Y. Age-related macular degeneration. Lancet. 2008;372:1835–1845. doi: 10.1016/S0140-6736(08)61759-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(08)61759-6</ArticleId><ArticleId IdType="pmc">PMC2603424</ArticleId><ArticleId IdType="pubmed">19027484</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim L.S., Mitchell P., Seddon J.M., Holz F.G., Wong T.Y. Age-related macular degeneration. Lancet. 2012;379:1728–1738. doi: 10.1016/S0140-6736(12)60282-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)60282-7</ArticleId><ArticleId IdType="pubmed">22559899</ArticleId></ArticleIdList></Reference><Reference><Citation>Domalpally A., Xing B., Pak J.W., Agrón E., Ferris F.L., 3rd, Clemons T.E., Chew E.Y. Extramacular Drusen and Progression of Age-Related Macular Degeneration: Age Related Eye Disease Study 2 Report 30. Ophthalmol. Retin. 2023;7:111–117. doi: 10.1016/j.oret.2022.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2022.08.001</ArticleId><ArticleId IdType="pmc">PMC9899297</ArticleId><ArticleId IdType="pubmed">35940477</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores R., Carneiro Â., Vieira M., Tenreiro S., Seabra M.C. Age-Related Macular Degeneration: Pathophysiology, Management, and Future Perspectives. Ophthalmologica. 2021;244:495–511. doi: 10.1159/000517520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000517520</ArticleId><ArticleId IdType="pubmed">34130290</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitch I.M., Gerometta M., Eichenbaum D., Finger R.P., Steinle N.C., Baldwin M.E. Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review. Ophthalmol. Ther. 2024;13:1857–1875. doi: 10.1007/s40123-024-00973-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40123-024-00973-4</ArticleId><ArticleId IdType="pmc">PMC11178757</ArticleId><ArticleId IdType="pubmed">38824253</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld P.J., Rich R.M., Lalwani G.A. Ranibizumab: Phase III clinical trial results. Ophthalmol. Clin. N. Am. 2006;19:361–372. doi: 10.1016/j.ohc.2006.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ohc.2006.05.009</ArticleId><ArticleId IdType="pubmed">16935211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Lo A.C. Diabetic retinopathy: Pathophysiology and treatments. Int. J. Mol. Sci. 2018;19:1816. doi: 10.3390/ijms19061816.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19061816</ArticleId><ArticleId IdType="pmc">PMC6032159</ArticleId><ArticleId IdType="pubmed">29925789</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong D.S., Aiello L.P., Ferris F.L., III, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27:2540–2553. doi: 10.2337/diacare.27.10.2540.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.27.10.2540</ArticleId><ArticleId IdType="pubmed">15451934</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta M., Bandello F. Diabetic retinopathy: A clinical update. Diabetologia. 2002;45:1617–1634. doi: 10.1007/s00125-002-0990-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-002-0990-7</ArticleId><ArticleId IdType="pubmed">12488951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris F.L., Davis M.D., Aiello L.M. Treatment of diabetic retinopathy. N. Engl. J. Med. 1999;341:667–678. doi: 10.1056/NEJM199908263410907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199908263410907</ArticleId><ArticleId IdType="pubmed">10460819</ArticleId></ArticleIdList></Reference><Reference><Citation>Akinsoji E., Goldhardt R., Galor A. A Glimpse into Uveitis in the Aging Eye: Pathophysiology, Clinical Presentation and Treatment Considerations. Drugs Aging. 2018;35:399–408. doi: 10.1007/s40266-018-0545-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40266-018-0545-3</ArticleId><ArticleId IdType="pmc">PMC5955816</ArticleId><ArticleId IdType="pubmed">29663152</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuartero-Martínez A., García-Otero X., Codesido J., Gómez-Lado N., Mateos J., Bravo S.B., Rodríguez-Fernández C.A., González-Barcia M., Aguiar P., Ortega-Hortas M., et al. Preclinical characterization of endotoxin-induced uveitis models using OCT, PET/CT and proteomics. Int. J. Pharm. 2024;662:124516. doi: 10.1016/j.ijpharm.2024.124516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2024.124516</ArticleId><ArticleId IdType="pubmed">39067549</ArticleId></ArticleIdList></Reference><Reference><Citation>Muñoz-Fernández S., Martín-Mola E. Uveitis. Best Pract. Res. Clin. Rheumatol. 2006;20:487–505. doi: 10.1016/j.berh.2006.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2006.03.008</ArticleId><ArticleId IdType="pubmed">16777578</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J.H.-M., Wakefield D. Uveitis: A global perspective. Ocul. Immunol. Inflamm. 2002;10:263–279. doi: 10.1076/ocii.10.4.263.15592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/ocii.10.4.263.15592</ArticleId><ArticleId IdType="pubmed">12854035</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vos A.F., van Haren M.A., Verhagen C., Hoekzema R., Kijlstra A. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat.  [(accessed on 8 July 2024)];Investig. Ophthalmol. Vis. Sci. 1994 35:1100–1106. Available online:  https://pubmed.ncbi.nlm.nih.gov/8125720/</Citation><ArticleIdList><ArticleId IdType="pubmed">8125720</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos Lacomba M., Marcos Martín C., Gallardo Galera J.M., Gómez Vidal M.A., Collantes Estévez E., Ramírez Chamond R., Omar M. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251–255. doi: 10.1159/000055677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000055677</ArticleId><ArticleId IdType="pubmed">11586057</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos M.F.C., Mirada G.S., do Couto J.O., de Oliveira Costa G., Rangel Rosa A.C., Gambeta Borges C.H., Crevelin E.J., de Araujo L.S., Bastos J.K., Veneziani R.C.S., et al. A validated ultra-performance liquid chromatography with tandem mass spectrometry method for the quantification of Brazilian green propolis main compounds. Nat. Prod. Res. 2024:1–7. doi: 10.1080/14786419.2024.2356654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14786419.2024.2356654</ArticleId><ArticleId IdType="pubmed">38768436</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung E.H., Fan J., Flynn H.W., Jr., Albini T.A. Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare. Clin. Ophthalmol. 2022;16:1–13. doi: 10.2147/OPTH.S336963.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S336963</ArticleId><ArticleId IdType="pmc">PMC8742614</ArticleId><ArticleId IdType="pubmed">35018092</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemieniuk R.A., Bartoszko J.J., Díaz Martinez J.P., Kum E., Qasim A., Zeraatkar D., Izcovich A., Mangala S., Ge L., Han M.A., et al. Antibody and cellular therapies for treatment of COVID-19: A living systematic review and network meta-analysis. BMJ. 2021;374:n2231. doi: 10.1136/bmj.n2231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2231</ArticleId><ArticleId IdType="pmc">PMC8459162</ArticleId><ArticleId IdType="pubmed">34556486</ArticleId></ArticleIdList></Reference><Reference><Citation>Braghiroli M.I., Sabbaga J., Hoff P.M. Bevacizumab: Overview of the literature. Expert Rev. Anticancer Ther. 2012;12:567–580. doi: 10.1586/era.12.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/era.12.13</ArticleId><ArticleId IdType="pubmed">22594892</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazazi-Hyseni F., Beijnen J.H., Schellens J.H. Bevacizumab. Oncologist. 2010;15:819–825. doi: 10.1634/theoncologist.2009-0317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2009-0317</ArticleId><ArticleId IdType="pmc">PMC3228024</ArticleId><ArticleId IdType="pubmed">20688807</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R.P., Avery R.L., Barakat M.R., Kim J.E., Kiss S. Evidence-Based Use of Bevacizumab in the Management of Neovascular Age-Related Macular Degeneration. Ophthalmic Surg. Lasers Imaging Retin. 2024;55:156–162. doi: 10.3928/23258160-20240108-01.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/23258160-20240108-01</ArticleId><ArticleId IdType="pubmed">38466965</ArticleId></ArticleIdList></Reference><Reference><Citation>Estarreja J., Mendes P., Silva C., Camacho P., Mateus V. Off-Label Use of Bevacizumab in Patients Diagnosed with Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. Pharmaceuticals. 2024;17:1000. doi: 10.3390/ph17081000.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph17081000</ArticleId><ArticleId IdType="pmc">PMC11357420</ArticleId><ArticleId IdType="pubmed">39204105</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Lumbreras A., Ghule P., Panchal R., Giannouchos T., Lockhart C.M., Brixner D. Real-world evidence in the use of Bevacizumab in age-related macular degeneration (ArMD): A scoping review. Int. Ophthalmol. 2023;43:4527–4539. doi: 10.1007/s10792-023-02853-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10792-023-02853-5</ArticleId><ArticleId IdType="pubmed">37606820</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumus G., Berhuni M., Ozturkmen C. The short-term effects of intravitreal bevacizumab injection on intraocular pressure, cornea, iridocorneal angle, and anterior chamber. Ther. Adv. Ophthalmol. 2022;14:25158414221133772. doi: 10.1177/25158414221133772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/25158414221133772</ArticleId><ArticleId IdType="pmc">PMC9634187</ArticleId><ArticleId IdType="pubmed">36340047</ArticleId></ArticleIdList></Reference><Reference><Citation>Blick S.K., Keating G.M., Wagstaff A.J. Ranibizumab. Drugs. 2007;67:1199–1206. doi: 10.2165/00003495-200767080-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-200767080-00007</ArticleId><ArticleId IdType="pubmed">17521219</ArticleId></ArticleIdList></Reference><Reference><Citation>Triantafylla M., Massa H.F., Dardabounis D., Gatzioufas Z., Kozobolis V., Ioannakis K., Perente I., Panos G.D. Ranibizumab for the treatment of degenerative ocular conditions. Clin. Ophthalmol. 2014;8:1187–1198. doi: 10.2147/opth.S40350.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/opth.S40350</ArticleId><ArticleId IdType="pmc">PMC4077856</ArticleId><ArticleId IdType="pubmed">25028531</ArticleId></ArticleIdList></Reference><Reference><Citation>Pershing S., Talwar N., Armenti S.T., Grubbs J., Jr., Rosenthal J.M., Dedania V.S., Stein J.D. Use of Bevacizumab and Ranibizumab for Wet Age-Related Macular Degeneration: Influence of CATT Results and Introduction of Aflibercept. Am. J. Ophthalmol. 2019;207:385–394. doi: 10.1016/j.ajo.2019.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2019.05.011</ArticleId><ArticleId IdType="pmc">PMC6856411</ArticleId><ArticleId IdType="pubmed">31100217</ArticleId></ArticleIdList></Reference><Reference><Citation>Parravano M., Costanzo E., Scondotto G., Trifirò G., Virgili G. Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update. BioDrugs. 2021;35:673–692. doi: 10.1007/s40259-021-00499-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-021-00499-2</ArticleId><ArticleId IdType="pubmed">34655434</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinfeld N. Adalimumab: A review of side effects. Expert Opin. Drug Saf. 2005;4:637–641. doi: 10.1517/14740338.4.4.637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14740338.4.4.637</ArticleId><ArticleId IdType="pubmed">16011443</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudwaleit M., Rødevand E., Holck P., Vanhoof J., Kron M., Kary S., Kupper H. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann. Rheum. Dis. 2009;68:696–701. doi: 10.1136/ard.2008.092585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.092585</ArticleId><ArticleId IdType="pmc">PMC2663712</ArticleId><ArticleId IdType="pubmed">18662932</ArticleId></ArticleIdList></Reference><Reference><Citation>Takase K., Ohno S., Ideguchi H., Uchio E., Takeno M., Ishigatsubo Y. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol. Int. 2011;31:243–245. doi: 10.1007/s00296-009-1178-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-009-1178-y</ArticleId><ArticleId IdType="pubmed">19816689</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Llopis M., García-Delpech S., Salom D., Udaondo P., Hernández-Garfella M., Bosch-Morell F., Quijada A., Romero F.J. Adalimumab therapy for refractory uveitis: A pilot study. J. Ocul. Pharmacol. Ther. 2008;24:351–361. doi: 10.1089/jop.2007.0104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jop.2007.0104</ArticleId><ArticleId IdType="pubmed">18476805</ArticleId></ArticleIdList></Reference><Reference><Citation>Winterfield L.S., Menter A. Infliximab. Dermatol. Ther. 2004;17:409–426. doi: 10.1111/j.1396-0296.2004.04044.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1396-0296.2004.04044.x</ArticleId><ArticleId IdType="pubmed">15379776</ArticleId></ArticleIdList></Reference><Reference><Citation>Miraldi Utz V., Bulas S., Lopper S., Fenchel M., Sa T., Mehta M., Ash D., Lovell D.J., Kaufman A.H. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis. Pediatr. Rheumatol. 2019;17:79. doi: 10.1186/s12969-019-0383-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-019-0383-9</ArticleId><ArticleId IdType="pmc">PMC6884783</ArticleId><ArticleId IdType="pubmed">31783768</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordero-Coma M., Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv. Ophthalmol. 2015;60:575–589. doi: 10.1016/j.survophthal.2015.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.survophthal.2015.06.004</ArticleId><ArticleId IdType="pubmed">26164735</ArticleId></ArticleIdList></Reference><Reference><Citation>Deitch I., Amer R., Tomkins-Netzer O., Habot-Wilner Z., Friling R., Neumann R., Kramer M. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies. Graefe’s Arch. Clin. Exp. Ophthalmol. 2018;256:801–808. doi: 10.1007/s00417-018-3928-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-018-3928-6</ArticleId><ArticleId IdType="pubmed">29455252</ArticleId></ArticleIdList></Reference><Reference><Citation>Maleki A., Sahawneh H.F., Ma L., Meese H., He Y., Foster C.S. Infliximab therapy with noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy. Retina. 2017;37:836–843. doi: 10.1097/IAE.0000000000001269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000001269</ArticleId><ArticleId IdType="pubmed">27681002</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham E.T., Jr. Exogenous factors influencing endogenous inflammation: What can patients do to improve control of their own uveitis? Br. J. Ophthalmol. 2010;94:813–814. doi: 10.1136/bjo.2009.178780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjo.2009.178780</ArticleId><ArticleId IdType="pubmed">20606019</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolz-Marco R., Gallego-Pinazo R., Díaz-Llopis M., Cunningham E.T., Jr., Arévalo J.F. Noninfectious uveitis: Strategies to optimize treatment compliance and adherence. Clin. Ophthalmol. 2015;9:1477–1481. doi: 10.2147/opth.S36650.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/opth.S36650</ArticleId><ArticleId IdType="pmc">PMC4547652</ArticleId><ArticleId IdType="pubmed">26316689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mushtaq B., Saeed T., Situnayake R.D., Murray P.I. Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye. 2007;21:824–825. doi: 10.1038/sj.eye.6702352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.eye.6702352</ArticleId><ArticleId IdType="pubmed">16601736</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorenç V., Mesquida M., Sainz de la Maza M., Blanco R., Calvo V., Maíz O., Blanco A., de Dios-Jiménez de Aberásturi J.R., Adán A. Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation. Ocul. Immunol. Inflamm. 2016;24:167–172. doi: 10.3109/09273948.2014.967779.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/09273948.2014.967779</ArticleId><ArticleId IdType="pubmed">25325834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.U., Shin W., Son J.Y., Yoo K.Y., Heo Y.S. Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases. Int. J. Mol. Sci. 2017;18:228. doi: 10.3390/ijms18010228.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18010228</ArticleId><ArticleId IdType="pmc">PMC5297857</ArticleId><ArticleId IdType="pubmed">28124979</ArticleId></ArticleIdList></Reference><Reference><Citation>Frías E.D., González J.F.D. Certolizumab pegol. Reumatol. Clin. 2011;6((Suppl. 3)):7–11. doi: 10.1016/j.reuma.2010.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2010.11.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Moisseiev E., Shulman S. Certolizumab-induced uveitis: A case report and review of the literature. Case Rep. Ophthalmol. 2014;5:54–59. doi: 10.1159/000358324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000358324</ArticleId><ArticleId IdType="pmc">PMC3975203</ArticleId><ArticleId IdType="pubmed">24707273</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharon Y., Chu D.S. Certolizumab pegol—Tumor necrosis factor inhibitor for refractory uveitis. Am. J. Ophthalmol. Case Rep. 2020;18:100633. doi: 10.1016/j.ajoc.2020.100633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajoc.2020.100633</ArticleId><ArticleId IdType="pmc">PMC7068621</ArticleId><ArticleId IdType="pubmed">32190782</ArticleId></ArticleIdList></Reference><Reference><Citation>Benschop R.J., Tuttle J.L., Zhang L., Poorbaugh J., Kallewaard N.L., Vaillancourt P., Crisp M., Trinh T.N.V., Freitas J.J., Beasley S., et al. The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. Sci. Transl. Med. 2022;14:eabn3041. doi: 10.1126/scitranslmed.abn3041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn3041</ArticleId><ArticleId IdType="pmc">PMC9210450</ArticleId><ArticleId IdType="pubmed">35679357</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb R.L., Nirula A., Chen P., Boscia J., Heller B., Morris J., Huhn G., Cardona J., Mocherla B., Stosor V., et al. Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021;325:632–644. doi: 10.1001/jama.2021.0202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.0202</ArticleId><ArticleId IdType="pmc">PMC7821080</ArticleId><ArticleId IdType="pubmed">33475701</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks E.D. Casirivimab/imdevimab: First approval. Drugs. 2021;81:2047–2055. doi: 10.1007/s40265-021-01620-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01620-z</ArticleId><ArticleId IdType="pmc">PMC8556815</ArticleId><ArticleId IdType="pubmed">34716907</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellas C., Del Bello A., Gaube G., Tremeaux P., Jeanne N., Ranger N., Martin-Blondel G., Delobel P., Kamar N., Izopet J. Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies. Open Forum Infect. Dis. 2022;9:ofac093. doi: 10.1093/ofid/ofac093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac093</ArticleId><ArticleId IdType="pmc">PMC8903465</ArticleId><ArticleId IdType="pubmed">35299988</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen J., Baum A., Pascal K.E., Russo V., Giordano S., Wloga E., Fulton B.O., Yan Y., Koon K., Patel K., et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369:1010–1014. doi: 10.1126/science.abd0827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0827</ArticleId><ArticleId IdType="pmc">PMC7299284</ArticleId><ArticleId IdType="pubmed">32540901</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumal C.R., Bodaghi B., Singer M., Tanzer D.J., Seres A., Joshi M.R., Feltgen N., Gale R. Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment. Ophthalmol. Retin. 2021;5:519–527. doi: 10.1016/j.oret.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2020.09.020</ArticleId><ArticleId IdType="pubmed">33007521</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugel P.U., Singh R.P., Koh A., Ogura Y., Weissgerber G., Gedif K., Jaffe G.J., Tadayoni R., Schmidt-Erfurth U., Holz F.G. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128:89–99. doi: 10.1016/j.ophtha.2020.06.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2020.06.028</ArticleId><ArticleId IdType="pubmed">32574761</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H.V., Li A.S., Silva A.R., Leng T. Ocular adverse events following intravitreal brolucizumab for neovascular age-related macular degeneration at a single tertiary care center. Eur. J. Ophthalmol. 2022;32:2747–2751. doi: 10.1177/11206721211059332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11206721211059332</ArticleId><ArticleId IdType="pmc">PMC10666666</ArticleId><ArticleId IdType="pubmed">34761684</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu Serhan H., Taha M.J.J., Abuawwad M.T., Abdelaal A., Irshaidat S., Abu Serhan L., Abu Salim Q.F., Awamleh N., Abdelazeem B., Elnahry A.G. Safety and Efficacy of Brolucizumab in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy: A Systematic Review and Meta-Analysis. Semin. Ophthalmol. 2024;39:251–260. doi: 10.1080/08820538.2023.2271095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820538.2023.2271095</ArticleId><ArticleId IdType="pubmed">37849309</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D.M., Emanuelli A., Bandello F., Barranco J.J.E., Figueira J., Souied E., Wolf S., Gupta V., Ngah N.F., Liew G., et al. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am. J. Ophthalmol. 2022;238:157–172. doi: 10.1016/j.ajo.2022.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2022.01.004</ArticleId><ArticleId IdType="pubmed">35038415</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano T., Kumazaki A., Tomihara R., Ito S., Hoshiyama K., Murata T. Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: A retrospective, single-center, observational study. Sci. Rep. 2023;13:10901. doi: 10.1038/s41598-023-37726-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-37726-5</ArticleId><ArticleId IdType="pmc">PMC10322981</ArticleId><ArticleId IdType="pubmed">37407660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo B.L., Singh R.P. Brolucizumab for the treatment of diabetic macular edema. Curr. Opin. Ophthalmol. 2022;33:167–173. doi: 10.1097/ICU.0000000000000849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ICU.0000000000000849</ArticleId><ArticleId IdType="pubmed">35266896</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R.P., Barakat M.R., Ip M.S., Wykoff C.C., Eichenbaum D.A., Joshi S., Warrow D., Sheth V.S., Stefanickova J., Kim Y.S., et al. Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023;141:1152–1160. doi: 10.1001/jamaophthalmol.2023.5248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2023.5248</ArticleId><ArticleId IdType="pubmed">37971723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferro Desideri L., Traverso C.E., Nicolò M., Munk M.R. Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration. Pharmaceutics. 2023;15:1413. doi: 10.3390/pharmaceutics15051413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15051413</ArticleId><ArticleId IdType="pmc">PMC10222467</ArticleId><ArticleId IdType="pubmed">37242655</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimura M., Kitano S., Ogata N., Mitamura Y., Oh H., Ochi H., Ohsawa S., Hirakata A., Bolz M., Findl O., et al. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial. Jpn. J. Ophthalmol. 2023;67:264–279. doi: 10.1007/s10384-023-00979-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10384-023-00979-8</ArticleId><ArticleId IdType="pmc">PMC9999055</ArticleId><ArticleId IdType="pubmed">36897413</ArticleId></ArticleIdList></Reference><Reference><Citation>Agostini H., Abreu F., Baumal C.R., Chang D.S., Csaky K.G., Demetriades A.M., Kodjikian L., Lim J.I., Margaron P., Monés J.M., et al. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: From preclinical studies to phase 3 outcomes. Graefe’s Arch. Clin. Exp. Ophthalmol. 2024 doi: 10.1007/s00417-024-06531-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-024-06531-9</ArticleId><ArticleId IdType="pubmed">38847896</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H., Inoda S., Takahashi H., Takahashi R., Hashimoto Y., Yoshida H., Kawashima H., Yanagi Y. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment. Sci. Rep. 2024;14:9087. doi: 10.1038/s41598-024-59894-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-59894-8</ArticleId><ArticleId IdType="pmc">PMC11032343</ArticleId><ArticleId IdType="pubmed">38643252</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanani A.M., Guymer R.H., Basu K., Boston H., Heier J.S., Korobelnik J.F., Kotecha A., Lin H., Silverman D., Swaminathan B., et al. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmol. Sci. 2021;1:100076. doi: 10.1016/j.xops.2021.100076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xops.2021.100076</ArticleId><ArticleId IdType="pmc">PMC9559073</ArticleId><ArticleId IdType="pubmed">36246941</ArticleId></ArticleIdList></Reference><Reference><Citation>Heier J.S., Khanani A.M., Quezada Ruiz C., Basu K., Ferrone P.J., Brittain C., Figueroa M.S., Lin H., Holz F.G., Patel V., et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–740. doi: 10.1016/S0140-6736(22)00010-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00010-1</ArticleId><ArticleId IdType="pubmed">35085502</ArticleId></ArticleIdList></Reference><Reference><Citation>Śpiewak D., Drzyzga Ł., Dorecka M., Wyględowska-Promieńska D. Summary of the Therapeutic Options for Patients with Dry and Neovascular AMD. J. Clin. Med. 2024;13:4227. doi: 10.3390/jcm13144227.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13144227</ArticleId><ArticleId IdType="pmc">PMC11278184</ArticleId><ArticleId IdType="pubmed">39064267</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCroos F.C., Reed D., Adam M.K., Salz D., Gupta O.P., Ho A.C., Regillo C.D. Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial. Am. J. Ophthalmol. 2017;180:142–150. doi: 10.1016/j.ajo.2017.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2017.06.002</ArticleId><ArticleId IdType="pubmed">28624325</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzetta P., Korobelnik J.F., Heier J.S., Leal S., Holz F.G., Clark W.L., Eichenbaum D., Iida T., Xiaodong S., Berliner A.J., et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141–1152. doi: 10.1016/S0140-6736(24)00063-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)00063-1</ArticleId><ArticleId IdType="pubmed">38461841</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams B.S., Sorhaitz W., Stringham J. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2023. Aflibercept.</Citation><ArticleIdList><ArticleId IdType="pubmed">35881741</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira Dias J.R., Badaró E., Novais E.A., Colicchio D., Chiarantin G.M., Matioli M.M., Verna C., Penha F.M., Barros N.M., Meyer C.H., et al. Preclinical investigations of intravitreal ziv-aflibercept. Ophthalmic Surg. Lasers Imaging Retin. 2014;45:577–584. doi: 10.3928/23258160-20141118-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/23258160-20141118-15</ArticleId><ArticleId IdType="pubmed">25423640</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer P.G., Albini T.A. Drug-related adverse effects of antivascular endothelial growth factor agents. Curr. Opin. Ophthalmol. 2021;32:191–197. doi: 10.1097/ICU.0000000000000757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ICU.0000000000000757</ArticleId><ArticleId IdType="pubmed">33770015</ArticleId></ArticleIdList></Reference><Reference><Citation>Avunduk M.C., Avunduk A.M., Oztekin E., Baltaci A.K., Ozyazgan Y., Mogolkoc R. Etanercept treatment in the endotoxin-induced uveitis of rats. Exp. Eye Res. 2004;79:357–365. doi: 10.1016/j.exer.2004.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2004.06.001</ArticleId><ArticleId IdType="pubmed">15336498</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim L.L., Fraunfelder F.W., Rosenbaum J.T. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56:3248–3252. doi: 10.1002/art.22918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22918</ArticleId><ArticleId IdType="pubmed">17907169</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Quintanilla L., Almuiña-Varela P., Maroñas O., Gil-Rodriguez A., Rodríguez-Cid M.J., Gil-Martinez M., Abraldes M.J., Gómez-Ulla de Irazazabal F., González-Barcia M., Mondelo-Garcia C., et al. Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration. Investig. Ophthalmol. Vis. Sci. 2023;64:34. doi: 10.1167/iovs.64.13.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.64.13.34</ArticleId><ArticleId IdType="pmc">PMC10599160</ArticleId><ArticleId IdType="pubmed">37862026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferro Desideri L., Traverso C.E., Nicolò M. Brolucizumab: A novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD. Expert Opin. Biol. Ther. 2021;21:553–561. doi: 10.1080/14712598.2021.1915278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2021.1915278</ArticleId><ArticleId IdType="pubmed">33899632</ArticleId></ArticleIdList></Reference><Reference><Citation>Markham A. Brolucizumab: First Approval. Drugs. 2019;79:1997–2000. doi: 10.1007/s40265-019-01231-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-019-01231-9</ArticleId><ArticleId IdType="pubmed">31768932</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepard H.M., Phillips G.L., Thanos C.D., Feldmann M. Developments in therapy with monoclonal antibodies and related proteins. Clin. Med. 2017;17:220–232. doi: 10.7861/clinmedicine.17-3-220.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.17-3-220</ArticleId><ArticleId IdType="pmc">PMC6297577</ArticleId><ArticleId IdType="pubmed">28572223</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamiya R., Hata M., Tanaka A., Tsuchikawa M., Ueda-Arakawa N., Tamura H., Miyata M., Takahashi A., Kido A., Muraoka Y., et al. Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci. Rep. 2023;13:21128. doi: 10.1038/s41598-023-48190-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-48190-6</ArticleId><ArticleId IdType="pmc">PMC10689783</ArticleId><ArticleId IdType="pubmed">38036627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaggi D., Nagamany T., Ebneter A., Munk M., Wolf S., Zinkernagel M. Aflibercept for age-related macular degeneration: 4-year outcomes of a ‘treat-and-extend’ regimen with exit-strategy. Br. J. Ophthalmol. 2022;106:246–250. doi: 10.1136/bjophthalmol-2020-316514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2020-316514</ArticleId><ArticleId IdType="pmc">PMC8788035</ArticleId><ArticleId IdType="pubmed">33127830</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng S., Zhang S., Huang M., Liu Y., Zou X., Chen X., Zhang Z. Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: Progress from mechanisms to clinical applications. Front. Med. 2024;11:1411278. doi: 10.3389/fmed.2024.1411278.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2024.1411278</ArticleId><ArticleId IdType="pmc">PMC11294244</ArticleId><ArticleId IdType="pubmed">39099595</ArticleId></ArticleIdList></Reference><Reference><Citation>Quah N.Q.X., Javed K., Arbi L., Hanumunthadu D. Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Clin. Ophthalmol. 2024;18:1479–1490. doi: 10.2147/OPTH.S463624.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S463624</ArticleId><ArticleId IdType="pmc">PMC11141735</ArticleId><ArticleId IdType="pubmed">38827773</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartzman S. Advancements in the management of uveitis. Best Pract. Res. Clin. Rheumatol. 2016;30:304–315. doi: 10.1016/j.berh.2016.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2016.07.005</ArticleId><ArticleId IdType="pubmed">27886802</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi A., Katelaris C. The use of biologic agents in the management of uveitis. Intern. Med. J. 2019;49:1352–1363. doi: 10.1111/imj.14215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.14215</ArticleId><ArticleId IdType="pubmed">30582273</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott I.U., VanVeldhuisen P.C., Ip M.S., Blodi B.A., Oden N.L., Awh C.C., Kunimoto D.Y., Marcus D.M., Wroblewski J.J., King J., et al. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients with Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA. 2017;317:2072–2087. doi: 10.1001/jama.2017.4568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.4568</ArticleId><ArticleId IdType="pmc">PMC5710547</ArticleId><ArticleId IdType="pubmed">28492910</ArticleId></ArticleIdList></Reference><Reference><Citation>Virgili G., Parravano M., Evans J.R., Gordon I., Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: A network meta-analysis. Cochrane Database Syst. Rev. 2017;6:1465–1858. doi: 10.1002/14651858.CD007419.pub5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD007419.pub5</ArticleId><ArticleId IdType="pmc">PMC6481463</ArticleId><ArticleId IdType="pubmed">28639415</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirley M. Faricimab: First Approval. Drugs. 2022;82:825–830. doi: 10.1007/s40265-022-01713-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-022-01713-3</ArticleId><ArticleId IdType="pubmed">35474059</ArticleId></ArticleIdList></Reference><Reference><Citation>Bressler N.M. Treatment of Macular Edema Due to Central Retinal Vein Occlusion: Another Score for Repackaged Bevacizumab. JAMA. 2017;317:2067–2069. doi: 10.1001/jama.2017.5899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.5899</ArticleId><ArticleId IdType="pubmed">28492939</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakzad-Vaezi K., Mehta H., Mammo Z., Tufail A. Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia. Expert Opin. Biol. Ther. 2016;16:873–881. doi: 10.1517/14712598.2016.1167868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2016.1167868</ArticleId><ArticleId IdType="pubmed">26985834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayanagi K., Uematsu S., Hara C., Wakabayashi T., Fukushima Y., Sato S., Ikuno Y., Nishida K. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization. Graefe’s Arch. Clin. Exp. Ophthalmol. 2019;257:749–757. doi: 10.1007/s00417-018-04214-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-018-04214-w</ArticleId><ArticleId IdType="pubmed">30643966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Moreno J.M., Montero J.A., Amat-Peral P. Myopic choroidal neovascularization treated by intravitreal bevacizumab: Comparison of two different initial doses. Graefe’s Arch. Clin. Exp. Ophthalmol. 2011;249:595–599. doi: 10.1007/s00417-010-1599-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-010-1599-z</ArticleId><ArticleId IdType="pubmed">21234588</ArticleId></ArticleIdList></Reference><Reference><Citation>Toto L., Di Antonio L., Costantino O., Mastropasqua R. Anti-VEGF Therapy in Myopic CNV. Curr. Drug Targets. 2021;22:1054–1063. doi: 10.2174/1389450122999210128180725.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450122999210128180725</ArticleId><ArticleId IdType="pubmed">33511955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng D.S.C., Fung N.S.K., Yip F.L.T., Lai T.Y.Y. Ranibizumab for myopic choroidal neovascularization. Expert Opin. Biol. Ther. 2020;20:1385–1393. doi: 10.1080/14712598.2021.1830969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2021.1830969</ArticleId><ArticleId IdType="pubmed">33003962</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>